Insider Buying: Xenon Pharmaceuticals Inc. (XENE) Director Purchases $33,300.00 in Stock
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Mohammad Azab purchased 15,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was acquired at an average cost of $2.22 per share, for a total transaction of $33,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Mohammad Azab also recently made the following trade(s):
- On Friday, September 22nd, Mohammad Azab bought 10,000 shares of Xenon Pharmaceuticals stock. The stock was bought at an average price of $2.95 per share, with a total value of $29,500.00.
- On Friday, August 18th, Mohammad Azab bought 6,335 shares of Xenon Pharmaceuticals stock. The stock was bought at an average price of $2.90 per share, with a total value of $18,371.50.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) traded up $0.15 during midday trading on Friday, hitting $2.40. 521,456 shares of the stock traded hands, compared to its average volume of 76,539. Xenon Pharmaceuticals Inc. has a 12 month low of $2.10 and a 12 month high of $9.95.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/19/insider-buying-xenon-pharmaceuticals-inc-xene-director-purchases-33300-00-in-stock.html.
Several equities research analysts recently weighed in on the stock. Jefferies Group LLC set a $5.00 target price on shares of Xenon Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 4th. Zacks Investment Research upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, October 5th.
Several hedge funds and other institutional investors have recently bought and sold shares of XENE. Renaissance Technologies LLC increased its holdings in shares of Xenon Pharmaceuticals by 90.1% during the first quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock worth $868,000 after buying an additional 102,890 shares in the last quarter. KCG Holdings Inc. acquired a new stake in shares of Xenon Pharmaceuticals during the first quarter worth approximately $122,000. K2 Principal Fund L.P. increased its holdings in shares of Xenon Pharmaceuticals by 40.6% in the second quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock valued at $518,000 after purchasing an additional 47,535 shares in the last quarter. DAFNA Capital Management LLC increased its holdings in shares of Xenon Pharmaceuticals by 11.2% in the second quarter. DAFNA Capital Management LLC now owns 377,695 shares of the biopharmaceutical company’s stock valued at $1,190,000 after purchasing an additional 38,081 shares in the last quarter. Finally, Scotia Capital Inc. increased its holdings in shares of Xenon Pharmaceuticals by 36.0% in the second quarter. Scotia Capital Inc. now owns 35,629 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 9,426 shares in the last quarter. 55.29% of the stock is owned by institutional investors.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Receive News & Stock Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.